# SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients

> **NCT00608868** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 156 (actual)

## Conditions studied

- Non Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT00608868
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2012-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00608868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00608868, "SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00608868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*